DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

6 8 9 8
ROE
30.63% 34.50% 35.62% 38.49%
ROA
10.40% 13.04% 13.90% 14.51%
ROIC
75.49% 28.66% 36.21% 37.13%
Return on Tangible Assets
21.48% 24.24% 25.37% 30.24%
Average Days of Receivables
89.68 95.21 82.47 92.38
Free Cash Flow per Share
2.72 2.76 3.71 3.68
Free Cash Flow
1,061.90 1,077.20 1,429.40 1,405.00
Other line items

Show all line items

Columns are period end dates